CY1119826T1 - Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη - Google Patents

Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη

Info

Publication number
CY1119826T1
CY1119826T1 CY20181100074T CY181100074T CY1119826T1 CY 1119826 T1 CY1119826 T1 CY 1119826T1 CY 20181100074 T CY20181100074 T CY 20181100074T CY 181100074 T CY181100074 T CY 181100074T CY 1119826 T1 CY1119826 T1 CY 1119826T1
Authority
CY
Cyprus
Prior art keywords
makitentani
compositions containing
therapeutic compositions
compound
pharmaceutically acceptable
Prior art date
Application number
CY20181100074T
Other languages
English (en)
Inventor
Martine Clozel
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41346591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119826(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of CY1119826T1 publication Critical patent/CY1119826T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αναφέρεται σε προϊόν που περιέχει την ένωση του τύπου (I) κατωτέρω ή ένα φαρμακευτικώς αποδεκτό άλας της εν λόγω ενώσεως, σε συνδυασμό με μία τουλάχιστον ένωση που έχει ιδιότητες αγωνιστή υποδοχέων προστακυκλίνης (IP), ή ένα φαρμακευτικώς αποδεκτό άλας αυτής.
CY20181100074T 2008-08-13 2018-01-19 Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη CY1119826T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008053252 2008-08-13
PCT/IB2009/053553 WO2010018549A2 (en) 2008-08-13 2009-08-12 Therapeutic compositions containing macitentan

Publications (1)

Publication Number Publication Date
CY1119826T1 true CY1119826T1 (el) 2018-06-27

Family

ID=41346591

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100074T CY1119826T1 (el) 2008-08-13 2018-01-19 Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη
CY20201100016T CY1122641T1 (el) 2008-08-13 2020-01-08 Θεραπευτικες συνθεσεις που περιεχουν macitentan

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100016T CY1122641T1 (el) 2008-08-13 2020-01-08 Θεραπευτικες συνθεσεις που περιεχουν macitentan

Country Status (29)

Country Link
US (3) US8809334B2 (el)
EP (2) EP3300729B1 (el)
JP (3) JP5764061B2 (el)
KR (1) KR101678699B1 (el)
CN (1) CN102099026B (el)
AR (1) AR073031A1 (el)
AU (1) AU2009280843B2 (el)
BR (1) BRPI0917661B8 (el)
CA (1) CA2731370C (el)
CY (2) CY1119826T1 (el)
DK (2) DK3300729T3 (el)
ES (2) ES2652590T3 (el)
HK (1) HK1253355B (el)
HR (2) HRP20171917T1 (el)
HU (2) HUE047767T2 (el)
IL (1) IL211143A0 (el)
LT (2) LT3300729T (el)
MA (1) MA32614B1 (el)
MX (1) MX350011B (el)
MY (1) MY178894A (el)
NO (1) NO2315587T3 (el)
NZ (1) NZ591601A (el)
PL (2) PL2315587T3 (el)
PT (2) PT3300729T (el)
RU (1) RU2519161C2 (el)
SI (2) SI3300729T1 (el)
TW (1) TWI446911B (el)
WO (1) WO2010018549A2 (el)
ZA (1) ZA201101900B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8729086B2 (en) 2008-02-28 2014-05-20 Nippon Shinyaku Co., Ltd. Fibrosis inhibitor
SI3300729T1 (sl) 2008-08-13 2020-02-28 Actelion Pharmaceuticals Ltd. Terapevtski sestavki, ki vsebujejo macitentan
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2014110491A1 (en) 2013-01-11 2014-07-17 Theratrophix Llc Prodrugs of treprostinil
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9794795B1 (en) 2016-04-29 2017-10-17 Corning Optical Communications Wireless Ltd Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
KR20240119159A (ko) * 2018-09-14 2024-08-06 파모사 바이오팜 인코포레이티드 약산성 약물의 방출 제어를 위한 약제학적 조성물 및 이의 용도
SI3897646T1 (sl) * 2018-12-21 2024-08-30 ACTELION PHARMACEUTICALS lTD, Makitentan za zdravljenje pljučne arterijske hipertenzije
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4539333A (en) * 1976-05-11 1985-09-03 Burroughs Wellcome Co. Prostacyclin, methods of using and method of making
DE2845770A1 (de) 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
US4683330A (en) * 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
ES2260318T3 (es) * 2000-12-18 2006-11-01 Actelion Pharmaceuticals Ltd. Nuevas sulfamidas y su utilizacion como antagonistas del receptor de endotelina.
AU2002229573A1 (en) * 2000-12-19 2002-07-01 Merck Patent Gmbh Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
DE10100426B4 (de) 2001-01-08 2006-04-06 Steag Hamatech Ag Verfahren und Vorrichtung zum Zusammenfügen von Substraten
TWI316055B (el) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
WO2004017993A1 (en) * 2002-08-12 2004-03-04 Actelion Pharmaceuticals Ltd Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
JP4769460B2 (ja) * 2002-12-02 2011-09-07 アクテリオン ファーマシューティカルズ リミテッド 新規スルファミド類
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
TW200628467A (en) * 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
SI2254570T1 (sl) 2008-02-20 2014-03-31 Actelion Pharmaceuticals Ltd. Kombinacija, obsegajoča paklitaksel, za zdravljenje raka na jajčnikih
SI3300729T1 (sl) 2008-08-13 2020-02-28 Actelion Pharmaceuticals Ltd. Terapevtski sestavki, ki vsebujejo macitentan

Also Published As

Publication number Publication date
RU2011109084A (ru) 2012-09-20
JP5764061B2 (ja) 2015-08-12
AR073031A1 (es) 2010-10-06
CN102099026A (zh) 2011-06-15
KR101678699B1 (ko) 2016-11-23
RU2519161C2 (ru) 2014-06-10
TW201010985A (en) 2010-03-16
JP2011530581A (ja) 2011-12-22
KR20110045006A (ko) 2011-05-03
MX350011B (es) 2017-08-22
AU2009280843A1 (en) 2010-02-18
WO2010018549A2 (en) 2010-02-18
CA2731370C (en) 2017-03-14
NO2315587T3 (el) 2018-03-24
NZ591601A (en) 2012-12-21
AU2009280843B2 (en) 2015-03-05
EP3300729A1 (en) 2018-04-04
WO2010018549A3 (en) 2010-07-29
HUE036071T2 (hu) 2018-06-28
PL3300729T3 (pl) 2020-04-30
SI3300729T1 (sl) 2020-02-28
US20110136818A1 (en) 2011-06-09
CN102099026B (zh) 2012-08-29
PT2315587T (pt) 2018-01-31
ES2763176T3 (es) 2020-05-27
US9597331B2 (en) 2017-03-21
BRPI0917661A2 (pt) 2015-12-01
HRP20192204T1 (hr) 2020-03-06
MX2011001625A (es) 2011-03-29
ZA201101900B (en) 2012-08-29
US20140329824A1 (en) 2014-11-06
HRP20171917T1 (hr) 2018-02-09
BRPI0917661B1 (pt) 2019-12-17
JP5956025B2 (ja) 2016-07-20
US8809334B2 (en) 2014-08-19
EP3300729B1 (en) 2019-10-09
US20160022678A1 (en) 2016-01-28
EP2315587B1 (en) 2017-10-25
HUE047767T2 (hu) 2020-05-28
LT2315587T (lt) 2018-01-10
EP2315587A2 (en) 2011-05-04
DK2315587T3 (en) 2018-01-02
JP2015187148A (ja) 2015-10-29
US9173881B2 (en) 2015-11-03
SI2315587T1 (en) 2018-04-30
JP5956026B2 (ja) 2016-07-20
MY178894A (en) 2020-10-21
LT3300729T (lt) 2020-01-10
DK3300729T3 (da) 2020-01-20
PL2315587T3 (pl) 2018-03-30
HK1253355B (zh) 2020-06-19
CY1122641T1 (el) 2021-03-12
ES2652590T3 (es) 2018-02-05
CA2731370A1 (en) 2010-02-18
HK1253355A1 (zh) 2019-06-14
IL211143A0 (en) 2011-04-28
MA32614B1 (fr) 2011-09-01
TWI446911B (zh) 2014-08-01
JP2015180683A (ja) 2015-10-15
PT3300729T (pt) 2020-01-20
BRPI0917661B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CY1119826T1 (el) Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη
CY1114983T1 (el) Συνθεση για τη θεραπεια της κυστικης ινωσης
CY1120089T1 (el) Παραγωγα ουριας ή φαρμακολογικως αποδεκτα αλατα εξ' αυτων χρησιμα ως αγωνιστες του παρομοιου με υποδοχεα πεπτιδιου φορμυλιου 1(fprl-1)
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CY1118231T1 (el) Συνθεση λιποσωματος
CY1115043T1 (el) Φαρμακευτικο σκευασμα
EA201070786A1 (ru) Бензофуропиримидиноны
CY1118307T1 (el) Συνθεσεις που περιλαμβανουν βουπρενορφινη (buprenorphine)
CY1112465T1 (el) Παραγωγα αμινοτριαζολης ως αγωνιστες alx
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
EA201170884A1 (ru) Производные пиперидина, пригодные в качестве антагонистов орексина
GT201400102A (es) 4-fenil-piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
CR11819A (es) Compuestos de isoindolina 5-sustituidos
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
CY1118365T1 (el) Διαμορφωτες διυδροπυραζολης του gpr40
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
CY1112724T1 (el) Παραγωγα ανθρακικης κουινουκλιδινης και ιατρικη συνθεση αυτων
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
CY1123722T1 (el) Ενεσιμα φαρμακευτικα σκευασματα λεφαμουλινης
EA201001882A1 (ru) Гидроксизамещенные тиенопиримидиноны как антагонисты рецептора-i меланинконцентрирующего гормона
CY1117826T1 (el) Ενωσεις μορφiνανης
CY1122321T1 (el) Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1
CY1121693T1 (el) Θετικοι αλλοστερικοι διαμορφωτες μουσκαρινικου υποδοχεα μ1